ZOLL Announces Acquisition of the Assets of CoAxia, Inc.

  ZOLL Announces Acquisition of the Assets of CoAxia, Inc.

  Expands Acute Critical Care Portfolio to Improve Patients’ Quality of Life

Business Wire

CHELMSFORD, Mass. -- July 1, 2013

ZOLL Medical Corporation, a manufacturer of medical devices and related
software solutions, announced today that it has purchased the assets of
CoAxia™, Inc., of Maple Grove, Minn., an early revenue stage medical device
company that provides catheter-based perfusion augmentation therapies to
improve outcomes for patients with cerebral ischemia resulting from vasospasm,
following subarachnoid hemorrhage.

The acquisition of intellectual property also includes several key patents on
cerebral perfusion augmentation as well as numerous other patents relevant to
other various vascular procedures.

The core application for CoAxia’s catheter technology, under the trade names
NeuroFlo™ and FloControl™, involves the redistribution of blood flow from the
lower extremities to support brain function during ischemia. These devices
also offer significant potential applications in blood flow redistribution for
trauma, cardiac arrest, coronary procedures, surgical blood loss, and renal

NeuroFlo and FloControl have regulatory clearances and reimbursement in the
United States. NeuroFlo has received Humanitarian Device Exemption approval
from the U.S. Food and Drug Administration (FDA) for use in patients with
vasospasm following subarachnoid hemorrhage. FloControl has also received
510(k) clearance for stopping and controlling blood flow in the peripheral

NeuroFlo and FloControl blood flow redistribution technology uses dual
balloons to create temporary partial obstruction in the descending aorta. This
technique causes a redistribution of cardiac output from the lower extremities
to the cerebral vasculature without significantly increasing arterial blood

The acquisition of CoAxia’s intellectual property offers synergy with ZOLL’s
acute critical care portfolio of products such as temperature management,
which may reduce reperfusion injury following ischemia by also using balloon
catheters. The use of temperature management in ischemic stroke patients is
being studied in several clinical trials ongoing and in development.

“NeuroFlo technology has the potential to address a large portion of the
population who suffer cerebral ischemia, offering a significant benefit to
patients and the healthcare system,” said James Palazzolo, President of ZOLL.
“Our task is to continue to develop the significant body of clinical evidence
started by CoAxia demonstrating the safety and efficacy of the NeuroFlo
catheter and, in the end, do what is necessary for it to be a standard
treatment option for hundreds of thousands of stroke patients worldwide.”

Palazzolo explained that ZOLL plans to conduct a follow-up to the SENTIS
(Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke) clinical trial
in the near future. The SENTIS trial did not achieve statistical significance
in its primary efficacy end point, but achieved the trial’s primary safety
endpoint, as well as demonstrated numerous positive signals for both safety
and efficacy using the NeuroFlo technology.

The SENTIS trial was conducted at leading stroke centers in North America and
Europe to determine if this proprietary method for increasing cerebral blood
flow could minimize the damage caused by ischemic stroke and improve outcomes
in patients up to 14 hours after the onset of their stroke. ZOLL will work
with the leading stroke centers and the US FDA to identify the next steps for
the NeuroFlo technology in ischemic stroke.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets
medical devices and software solutions that help advance emergency care and
save lives, while increasing clinical and operational efficiencies. With
products for defibrillation and monitoring, circulation and CPR feedback, data
management, fluid resuscitation, and therapeutic temperature management, ZOLL
provides a comprehensive set of technologies that help clinicians, EMS and
fire professionals, and lay rescuers treat victims needing resuscitation and
critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers, homes
and construction materials, electronics, and health care business sectors. Its
health care operations include devices and systems for critical care,
dialysis, therapeutic apheresis, transfusion, and manufacture of
biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and
nutritional products. With more than 25,000 employees around the world, the
Asahi Kasei Group serves customers in more than 100 countries. For more
information, visit www.asahi-kasei.co.jp/asahi/en/.

Copyright © 2013 ZOLL Medical Corporation. All rights reserved. ZOLL, CoAxia,
FloControl, and NeuroFlow are trademarks or registered trademarks of ZOLL
Medical Corporation or its subsidiaries in the United States and/or other
countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation.
All trademarks are the property of their respective owners.


Media Contact:
ZOLL Medical Corporation
Diane Egan, +1 978-421-9637
Press spacebar to pause and continue. Press esc to stop.